Product Reports Resources Pricing Login Book a demo

Andromeda Surgical

Health Tech & Medtech · San Francisco, United States · Founded 2023

We are building autonomous robots for safer, better, faster surgery MoreLess

Andromeda Surgical, an entity operating within the medical technology sector, was incorporated with the objective of advancing surgical procedures through the application of robotics. The company was founded in May 2022 by Dr. Samer Abboud and Dr. Omri Lubovsky.

The founders bring a blend of medical and technological expertise to the venture. Dr. Samer Abboud, who serves as CEO, has a background as a senior orthopedic surgeon specializing in knee and hip arthroplasty, and also holds an MBA. This combination of clinical experience and business acumen informs the company's strategic direction. Dr. Omri Lubovsky, the CTO, possesses a Ph.D. in Computer Science, specializing in surgical robotics from The Technion – Israel Institute of Technology, providing the deep technical knowledge necessary for product development.

Andromeda Surgical is developing an autonomous robotic system designed to assist in orthopedic surgeries. The core of their offering is a platform that utilizes advanced imaging, artificial intelligence, and autonomous robotics to perform specific surgical tasks. This system is intended to enhance precision and efficiency during operations. The business model appears to be centered on the development and subsequent sale or lease of this specialized surgical equipment to hospitals and surgical centers. The target clients are primarily orthopedic surgeons and healthcare institutions looking to adopt advanced surgical technologies.

The company's product aims to provide real-time, intra-operative data to surgeons, enabling more informed decision-making. By automating certain aspects of the surgical workflow, the system is designed to improve procedural accuracy and potentially reduce surgery times. A key feature is its focus on a compact, radiation-free system, which addresses common concerns regarding the large footprint and imaging requirements of existing robotic platforms. Andromeda Surgical has secured initial funding, including a pre-seed round and grants from the Israel Innovation Authority, which has supported its early-stage research and development efforts.

Keywords: surgical robotics, orthopedic surgery, medical technology, autonomous systems, arthroplasty, medical devices, surgical navigation, artificial intelligence, healthcare robotics, medtech

Talent graph

Andromeda Surgical's talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Andromeda Surgical's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Pioneer Fund
Y Combinator
Series A 4 investors entered at this stage
Standard Capital
Vox Capital
Alumni Ventures
WestWave Capital

Global footprint

Where Andromeda Surgical has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States90%
🇦🇪 United Arab Emirates10%
2 countries shown

Market sentiment

What the market is saying about Andromeda Surgical

An AI-synthesized read of the highest-engagement posts about Andromeda Surgical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Andromeda Surgical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.